title: Botulinum Toxin to Treat Neurogenic Bladder.
abstract: Alteration in neural control from suprapontine areas to the nerves innervating the bladder can lead to bladder dysfunction and the development of a neurogenic bladder (NGB). Patients with NGB often suffer from urinary incontinence, which can lead to adverse events such as urinary tract infections and decubiti, in addition to creating a large care burden for family members or healthcare providers and significantly impairing patient quality of life. The common failure of anticholinergic medications has spurned the development of second-line treatments, including the use of botulinum toxin. OnabotulinumtoxinA (onaBoNT-A; BOTOX, Allergan, Inc.) was approved by the U.S. Food and Drug Administration (FDA) in 2011 to treat neurogenic detrusor overactivity in patients with urinary incontinence resulting from a NGB. In this review the authors summarize pertinent results from key trials leading to FDA approval of onaBoNT-A as well as more recent long-term data.
authors: Scott Department of Urology, Baylor College of Medicine, Houston, Texas.
authors: Christopher P
authors: CP
authors: Smith
authors: Department of Urology, Director of Neurourology, Oakland University William Beaumont School of Medicine, Royal Oak, Michigan.
authors: Michael B
authors: MB
authors: Chancellor
mesh_terms: D065087:Acetylcholine Release Inhibitors / Q000008:administration & dosage; D000283:Administration, Intravesical; D000818:Animals; D019274:Botulinum Toxins, Type A / Q000008:administration & dosage*; D002986:Clinical Trials as Topic; D006801:Humans; D001750:Urinary Bladder, Neurogenic / Q000175:diagnosis* / Q000188:drug therapy* / Q000503:physiopathology
chemical_list: D065087:Acetylcholine Release Inhibitors; D019274:Botulinum Toxins, Type A